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MedDRA: Medical Dictionary for Regulatory Activities. n = Number of subjects with at least one TEAE in each category (subjects with multiple AEs in each category are counted only once in each category). E = Number of cases in each category (events) . N = Total number of subjects in the relevant analysis population. % = Percentage of subjects with at least one TEAE in each category relative to the total number of subjects in the relevant analysis population. Treatment-emergent adverse events (TEAEs): Defined as AEs which started or worsened on or after the first study drug administration up to and including 14 days after the last study drug administration. TEAEs leading to death: Defined as TEAEs for which outcome is indicated as fatal. Serious TEAEs: Defined as TEAEs for which serious is indicated as yes. #: Indicates TEAEs of special interest. TEAEs of special interest: Identified by pre-specified SMQ codes as confirmed by TB Alliance. METABOLISM AND NUTRITION DISORDERS n (%) E 4 ( 3.7) 4 HYPOGLYCAEMIA n (%) E 2 ( 1.8) 2 ABNORMAL LOSS OF WEIGHT n (%) E 1 ( 0.9) 1 #LACTIC ACIDOSIS n (%) E 1 ( 0.9) 1 NERVOUS SYSTEM DISORDERS n (%) E 4 ( 3.7) 4 #GENERALISED TONIC-CLONIC SEIZURE n (%) E 1 ( 0.9) 1 #OPTIC NEURITIS n (%) E 1 ( 0.9) 1 #SEIZURE n (%) E 1 ( 0.9) 1 #SYNCOPE n (%) E 1 ( 0.9) 1 BLOOD AND LYMPHATIC SYSTEM DISORDERS n (%) E 3 ( 2.8) 3 #ANAEMIA n (%) E 2 ( 1.8) 2 #NEUTROPENIA n (%) E 1 ( 0.9) 1 RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS n (%) E 3 ( 2.8) 4 ASTHMA n (%) E 1 ( 0.9) 1 DYSPNOEA n (%) E 1 ( 0.9) 1 HAEMOPTYSIS n (%) E 1 ( 0.9) 1
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